Aristotle University Of Thessaloniki (AUTH)
Η επίδραση της ενδοπεριτοναϊκής έγχυσης της ρεγοραφενίμπης στην περιτοναϊκή διασπορά του καρκίνου του παχέος εντέρου μετά κυτταρομείωση σε επίμυες
Abstract
dc:descriptionIntroduction: Peritoneal metastases are the 3rd most common site of metastasis in colorectal cancer, after the liver and lungs, and are associated with a very poor prognosis and quality of life. Cytoreduction combined with intraperitoneal chemotherapy is the most effective treatment strategy in selected patients with resectable colorectal cancer and peritoneal dissemination. Regorafenib is an orally administered, pleiotropic, chemotherapeutic agent with a role in colon cancer non-responsive to conventional regimens. The purpose of this experimental study is to estimate the safety and effectiveness profile of its intraperitoneal administration in an experimental model. Methods: This study is a randomized, prospective, double-blind trial in rats. It begins with the cultivation of the HT-29 cancer cell line and their implantation in the peritoneal cavity of 48 rats, on day 0 (T0). After 28 days (T1), the animals were randomly and equally allocated into 4 groups of 12. Group A underwent median laparotomy and intraperitoneal administration of NaCl 0.9%, group B cytoreduction (CRS), group C intraperitoneal chemotherapy (IPEC) with regorafenib and group D CRS + IPEC. After 28 more days (T2), the animals were sacrificed, and various parameters such as body weight (BW), peritoneal carcinomatosis index (ePCI) and ascites’ weight were estimated. Results: At T1, all groups of rats showed BW without significant difference and developed peritoneal carcinomatosis to a similar extent. At T2, however, significant BW differences emerged between the experimental groups and the control group, as well as a difference in the comparison of group B vs D (p<0.05). ePCI was significantly reduced in group B (7±2.1) and D (5.7±1.9) compared to the other groups, but no significant difference was observed between them (p>0.05). The same pattern was observed in IL-6 and TNF-α levels, while in ascites weight a significant difference emerged between all groups (p<0.05).Conclusions: IPEC with regorafenib seems to be feasible and safe, with no significant toxicity in rats, and there seems to be some additive effect when combined with CRS. Further research is required before we can assess its effect on humans.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bitsianis, Stefanos
- Μπιτσιάνης, Στέφανος
Subjects
dc:subject × 20- Ενδοπεριτοναϊκή χημειοθεραπεία
- Ενδοπεριτοναϊκή χορήγηση
- Ρεγοραφενίμπη
- Περιτοναϊκή καρκινωμάτωση
- Ορθοκολικός καρκίνος
- Καρκίνος παχέος εντέρου
- Intraperitoneal chemotherapy
- Intraperitoneal administration
- Regorafenib
- Colorectal cancer
- Colon cancer
- Peritoneal carcinomatosis
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Χειρουργική
- Clinical Medicine
- Medical and Health Sciences
- Oncology
- Surgery
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55299